| Literature DB >> 22170936 |
Barbara A Brown-Elliott1, Jon Biehle, Patricia S Conville, Samuel Cohen, Michael Saubolle, Den Sussland, Nancy Wengenack, Kimberly Kriel, Linda Bridge, Steven McNulty, Ravikiran Vasireddy, Richard J Wallace.
Abstract
Recent reports of increasing in vitro sulfonamide resistance in Nocardia prompted us to investigate the findings. Despite the reports, there is a paucity of clinical reports of sulfonamide failure in treatment of nocardia disease. We reviewed 552 recent susceptibilities of clinical isolates of Nocardia from six major laboratories in the United States, and only 2% of the isolates were found to have resistant MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole. We hypothesize that the discrepancies in the apparent sulfonamide resistance between our study and the previous findings may be associated with difficulty in the laboratory interpretation of in vitro MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and the lack of quality controls for Nocardia for these agents.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22170936 PMCID： PMC3295118 DOI： 10.1128/JCM.06243-11
Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948